Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil. 04/25/2024 - 8:30 am | View Link